JP2013522367A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522367A5
JP2013522367A5 JP2013501396A JP2013501396A JP2013522367A5 JP 2013522367 A5 JP2013522367 A5 JP 2013522367A5 JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013501396 A JP2013501396 A JP 2013501396A JP 2013522367 A5 JP2013522367 A5 JP 2013522367A5
Authority
JP
Japan
Prior art keywords
cem
diffraction pattern
powder diffraction
ray powder
peaks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013501396A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522367A (ja
JP5711352B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/029424 external-priority patent/WO2011119604A1/en
Publication of JP2013522367A publication Critical patent/JP2013522367A/ja
Publication of JP2013522367A5 publication Critical patent/JP2013522367A5/ja
Application granted granted Critical
Publication of JP5711352B2 publication Critical patent/JP5711352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013501396A 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用 Active JP5711352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31606310P 2010-03-22 2010-03-22
US61/316,063 2010-03-22
PCT/US2011/029424 WO2011119604A1 (en) 2010-03-22 2011-03-22 Crystalline forms of a macrolide, and uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231987A Division JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用

Publications (3)

Publication Number Publication Date
JP2013522367A JP2013522367A (ja) 2013-06-13
JP2013522367A5 true JP2013522367A5 (enExample) 2014-05-15
JP5711352B2 JP5711352B2 (ja) 2015-04-30

Family

ID=44673574

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013501396A Active JP5711352B2 (ja) 2010-03-22 2011-03-22 マクロライドの結晶形、およびその使用
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014231987A Active JP6121387B2 (ja) 2010-03-22 2014-11-14 マクロライドの結晶形、およびその使用
JP2016244733A Pending JP2017081953A (ja) 2010-03-22 2016-12-16 マクロライドの結晶形、およびその使用
JP2019163614A Pending JP2020002168A (ja) 2010-03-22 2019-09-09 マクロライドの結晶形、およびその使用

Country Status (19)

Country Link
US (4) US8975386B2 (enExample)
EP (2) EP3009442B1 (enExample)
JP (4) JP5711352B2 (enExample)
KR (2) KR102006200B1 (enExample)
CN (2) CN108570083A (enExample)
AU (2) AU2011232627B2 (enExample)
BR (1) BR112012023950A2 (enExample)
CA (1) CA2793884C (enExample)
DK (1) DK2550286T3 (enExample)
ES (1) ES2564097T3 (enExample)
HR (1) HRP20160168T1 (enExample)
IL (1) IL222018B (enExample)
MX (1) MX361413B (enExample)
MY (1) MY162411A (enExample)
NZ (1) NZ602544A (enExample)
PL (1) PL2550286T3 (enExample)
RU (1) RU2650883C2 (enExample)
SI (1) SI2550286T1 (enExample)
WO (1) WO2011119604A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3738591A3 (en) 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
DK2358379T3 (en) 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
EP2475253B1 (en) 2009-09-10 2016-10-26 Cempra Pharmaceuticals, Inc. Methods for treating malaria, tuberculosis and mac diseases
BR112012023950A2 (pt) * 2010-03-22 2016-07-05 Cempra Pharmaceuticals Inc formas cristalinas de um macrolídeo, e usos dos mesmos
PL2571506T3 (pl) 2010-05-20 2017-10-31 Cempra Pharmaceuticals Inc Sposoby sporządzania makrolidów i ketolidów oraz ich produktów pośrednich
US9815863B2 (en) 2010-09-10 2017-11-14 Cempra Pharmaceuticals, Inc. Hydrogen bond forming fluoro ketolides for treating diseases
MX2014011537A (es) 2012-03-27 2015-02-10 Cempra Pharmaceuticals Inc Formulaciones parenterales para la administracion de antibioticos macrolidos.
WO2014152326A1 (en) 2013-03-14 2014-09-25 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
BR112015023670A2 (pt) 2013-03-15 2017-07-18 Cempra Pharmaceuticals Inc processo para preparar um composto
BR112015025159A2 (pt) 2013-04-04 2017-07-18 Harvard College macrolídeos e métodos de sua preparação e uso
US20170224664A1 (en) * 2014-08-05 2017-08-10 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
CN104151382B (zh) * 2014-08-08 2016-09-14 广东东阳光药业有限公司 一种固态大环内酯的晶型
CN104311611B (zh) * 2014-08-13 2017-01-18 广东东阳光药业有限公司 一种制备固态大环内酯的方法
HK1242920A1 (zh) 2014-10-08 2018-07-06 哈佛大学的校长及成员们 14-元酮内酯及其制备和使用方法
WO2016154591A1 (en) 2015-03-25 2016-09-29 President And Fellows Of Harvard College Macrolides with modified desosamine sugars and uses thereof
JP6112696B1 (ja) * 2015-10-05 2017-04-12 富山化学工業株式会社 ソリスロマイシンを含む錠剤
EP3190122A1 (en) * 2016-01-08 2017-07-12 LEK Pharmaceuticals d.d. A novel synthetic pathway towards solithromycin and purification thereof
WO2018045294A1 (en) * 2016-09-02 2018-03-08 Cempra Pharmaceuticals, Inc. Processes for preparing fluoroketolides
CA3163337A1 (en) * 2019-12-02 2021-06-10 AliquantumRx, Inc. Salts and polymorphs of cethromycin for the treatment of disease salts and polymorphs of cethromycin

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
US4474768A (en) 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US4742049A (en) 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL99995A (en) 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
US5985844A (en) 1992-03-26 1999-11-16 Merck & Co., Inc. Homoerythromycin A derivatives modified at the 4"-and 8A-positions
FR2697524B1 (fr) 1992-11-05 1994-12-23 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5527780A (en) 1992-11-05 1996-06-18 Roussel Uclaf Erythromycin derivatives
FR2718450B1 (fr) 1994-04-08 1997-01-10 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
FR2719587B1 (fr) 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
FR2739620B1 (fr) 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
FR2742757B1 (fr) 1995-12-22 1998-01-30 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2745290B1 (fr) 1996-02-28 1998-04-03 Roussel Uclaf Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
ATE296831T1 (de) 1996-09-04 2005-06-15 Abbott Lab 6-0-substituierte ketoliden mit antibakteriellen wirkung
US6407074B1 (en) 1997-06-11 2002-06-18 Pfizer Inc C-4″-substituted macrolide derivatives
EP0988308A1 (en) 1997-06-11 2000-03-29 Pfizer Products Inc. 9-oxime erythromycin derivatives
HN1998000086A (es) 1997-06-11 1999-03-08 Pfizer Prod Inc Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1998000159A (es) 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
IL135792A0 (en) 1997-12-01 2001-05-20 Abbott Lab 6-o-alkyl derivatives of erythronolide b
FR2777282B1 (fr) 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
US6020521A (en) 1998-08-26 2000-02-01 Abbott Laboratories Macrolide LHRH antagonists
US6387885B1 (en) 1998-08-26 2002-05-14 Abbott Laboratories 3′,3′-N-bis-desmethyl-3′-N-cycloalkyl erythromycin derivatives as LHRH antagonists
FR2785612A1 (fr) 1998-11-10 2000-05-12 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR2786188B1 (fr) 1998-11-24 2002-10-31 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur applicaion comme medicaments
KR100317907B1 (ko) 1998-11-24 2001-12-24 김 완 주 신규한 중간체, 이를 이용한 마크로라이드계 항생제의제조방법
EP1137654A1 (en) 1998-12-10 2001-10-04 Pfizer Products Inc. Carbamate and carbazate ketolide antibiotics
AP2001002222A0 (en) 1999-01-27 2001-09-30 Pfizer Prod Inc Ketolide antibiotics.
CA2411293A1 (en) 1999-01-28 2000-07-28 Pfizer Products Inc. Novel azalides and methods of making same
JP2002542197A (ja) 1999-04-16 2002-12-10 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド ケトライド抗菌剤
AU775637B2 (en) 1999-04-16 2004-08-12 Kosan Biosciences, Inc. Macrolide antiinfective agents
US6420535B1 (en) 1999-06-07 2002-07-16 Abbott Laboratories 6-O-carbamate ketolide derivatives
US6437106B1 (en) 1999-06-24 2002-08-20 Abbott Laboratories Process for preparing 6-o-substituted erythromycin derivatives
AU6183700A (en) 1999-08-06 2001-03-05 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
KR100336447B1 (ko) 1999-11-24 2002-05-15 민경윤 클라리스로마이신의 개선된 제조방법
JP2001261694A (ja) 2000-03-06 2001-09-26 Pfizer Prod Inc ケトライド抗生物質
MXPA02008861A (es) * 2000-03-15 2003-02-10 Hanmi Pharm Ind Co Ltd Metodo para preparar claritromicina de cristales de forma ii.
US20020115621A1 (en) 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
GB0031312D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Macrolides
US20030143162A1 (en) 2001-05-18 2003-07-31 Speirs Robert John Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
JP4509553B2 (ja) 2001-07-03 2010-07-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗菌活性を有するｃ１２修飾エリスロマイシンマクロライドおよびケトライド
US20030176327A1 (en) 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
MXPA04008173A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulaciones de farmaco antibiotico oftalmico que contienen un compuesto de ciclodextrina y cloruro de cetil piridinio.
ES2566761T3 (es) 2002-05-30 2016-04-15 The Scripps Research Institute Ligación de azidas y acetilenos catalizada por cobre
TW200420573A (en) 2002-09-26 2004-10-16 Rib X Pharmaceuticals Inc Bifunctional heterocyclic compounds and methods of making and using same
ITMI20022292A1 (it) 2002-10-29 2004-04-30 Zambon Spa 9a-azalidi ad attivita' antiinfiammatoria.
EP3738591A3 (en) * 2003-03-10 2021-03-24 Merck Sharp & Dohme Corp. Novel antibacterial agents
US7163924B2 (en) 2003-04-25 2007-01-16 Chiron Corporation Ketolide derivatives
WO2005007143A2 (en) 2003-07-14 2005-01-27 The Board Of Trustees Of The University Of Illinois Use of makrolides and ketolides for the treatment of tuberculosis
US7457520B2 (en) 2003-07-24 2008-11-25 Time Warner Cable, Inc. Technique for providing a virtual digital video recorder service through a communications network
US20060116336A1 (en) 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
ATE373009T1 (de) 2004-04-28 2007-09-15 Alembic Ltd Verfahren zur vorbereitung von telithromycin
BRPI0513903A (pt) 2004-07-28 2008-05-20 Ranbaxy Lab Ltd derivados de cetolìdeos úteis como agentes antimicrobianos, seus processos de preparação e composições farmacêuticas compreendendo os mesmos
EA011281B1 (ru) * 2004-12-21 2009-02-27 Пфайзер Продактс Инк. Макролиды
EP1835921B1 (en) 2005-01-14 2010-08-18 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
WO2007039914A2 (en) 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
WO2007059307A2 (en) * 2005-11-15 2007-05-24 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of telithromycin
US20090075916A1 (en) 2005-11-23 2009-03-19 Upadhyay Dilip J Use of Macrolide Derivatives for Treating Acne
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CN101129383B (zh) 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
US7742562B2 (en) * 2007-06-27 2010-06-22 Accuray Incorporated Lower-torso assembly of a treatment couch useable in an X-ray environment
EP2220104A1 (en) 2007-10-25 2010-08-25 Sandoz AG Process for the production of telithromycin
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
DK2358379T3 (en) * 2008-10-24 2016-03-07 Cempra Pharmaceuticals Inc BIOFORSVAR USING TRIAZOLHOLDIGE macrolides
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
BR112012023950A2 (pt) * 2010-03-22 2016-07-05 Cempra Pharmaceuticals Inc formas cristalinas de um macrolídeo, e usos dos mesmos

Similar Documents

Publication Publication Date Title
JP2013522367A5 (enExample)
JP2012144574A5 (enExample)
PH12014500164A1 (en) Compounds for the treatment and prophylaxis of respiratory syncytial virus disease
JP2013525444A5 (enExample)
WO2013040286A3 (en) Pharmaceutical compositions
CN104024227B8 (zh) 抑制脯氨酸羟化酶活性的化合物的晶型及其应用
WO2012021796A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
WO2012142093A3 (en) 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
WO2013066839A3 (en) Compounds and methods
WO2013019561A8 (en) Nuclear transport modulators and uses thereof
JP2011037901A5 (enExample)
WO2012083122A8 (en) Inhibitors of influenza viruses replication
PE20120989A1 (es) Sales de disacarina, acido difumarico, acido d-1-hidroxi-2-naftoico y monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino) pirimidin-5-il) metil) fenil) acetato de 4-(dimetilamino) butilo
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
EA033054B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
WO2010107807A3 (en) Compounds for treating inflammation and pain
WO2010129057A8 (en) Tetracycline compounds
JP2011088926A5 (enExample)